X4 Pharmaceuticals Inc
XFOR
Get informed when a big investor buys or sells
+ FollowMarket Cap$360.3M
Close$
$2.67
27.6% downside
Current Fair Value
27.6% downsideOvervalued by 27.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $360.30 Million |
|---|---|
| Enterprise Value | $145.04 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.87 |
| Beta | 0.35 |
| Outstanding Shares | 126,288,723 |
Return
| Return on Equity | -59.20% |
|---|---|
| Return on Assets | -36.90% |
| Return on Invested Capital | -45.69% |
Valuation & Multiples
| P/E Ratio | -0.84 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | 3.7 |
| Enterprise Value to Revenue | 16.09 |
| Enterprise Value to EBIT | -1.29 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$3.20 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$2.42 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 71.61%▼ 1087.43% |
|---|---|
| Total Invested | $373.74M▲ 8.75% |
| Investors Holding | 81▲ 5.00% |
ESG Score
No data
About X4 Pharmaceuticals Inc
72 employeesX4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare di...